Jiangxi Fushine Pharmaceutical Co Ltd (SHE:300497) — Market Cap & Net Worth
Market Cap & Net Worth: Jiangxi Fushine Pharmaceutical Co Ltd (300497)
Jiangxi Fushine Pharmaceutical Co Ltd (SHE:300497) has a market capitalization of $1.25 Billion (CN¥8.56 Billion) as of August 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #7857 globally and #1752 in its home market, demonstrating a -6.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangxi Fushine Pharmaceutical Co Ltd's stock price CN¥15.90 by its total outstanding shares 538648934 (538.65 Million). See Jiangxi Fushine Pharmaceutical Co Ltd capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Jiangxi Fushine Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Jiangxi Fushine Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $553.17 Million to $1.25 Billion (15.01% CAGR).
Jiangxi Fushine Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangxi Fushine Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.01x
Jiangxi Fushine Pharmaceutical Co Ltd's market cap is 1.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.13 Billion | $763.69 Million | $173.91 Million | 1.48x | 6.50x |
| 2017 | $713.50 Million | $958.15 Million | $177.55 Million | 0.74x | 4.02x |
| 2018 | $720.18 Million | $1.16 Billion | $194.72 Million | 0.62x | 3.70x |
| 2019 | $908.53 Million | $1.35 Billion | $305.84 Million | 0.67x | 2.97x |
| 2020 | $1.11 Billion | $1.49 Billion | $319.30 Million | 0.74x | 3.47x |
| 2021 | $1.29 Billion | $1.43 Billion | $48.83 Million | 0.90x | 26.36x |
| 2022 | $1.04 Billion | $1.65 Billion | -$141.47 Million | 0.63x | N/A |
| 2023 | $737.77 Million | $1.61 Billion | -$200.80 Million | 0.46x | N/A |
| 2024 | $657.37 Million | $1.18 Billion | -$272.10 Million | 0.56x | N/A |
| 2025 | $1.19 Billion | $1.18 Billion | -$53.07 Million | 1.01x | N/A |
Competitor Companies of 300497 by Market Capitalization
Companies near Jiangxi Fushine Pharmaceutical Co Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Jiangxi Fushine Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Jiangxi Fushine Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jiangxi Fushine Pharmaceutical Co Ltd's market cap moved from $553.17 Million to $ 1.25 Billion, with a yearly change of 15.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.25 Billion | +5.23% |
| 2025 | CN¥1.19 Billion | +81.18% |
| 2024 | CN¥657.37 Million | -10.90% |
| 2023 | CN¥737.77 Million | -29.09% |
| 2022 | CN¥1.04 Billion | -19.17% |
| 2021 | CN¥1.29 Billion | +16.29% |
| 2020 | CN¥1.11 Billion | +21.83% |
| 2019 | CN¥908.53 Million | +26.15% |
| 2018 | CN¥720.18 Million | +0.94% |
| 2017 | CN¥713.50 Million | -36.84% |
| 2016 | CN¥1.13 Billion | +104.22% |
| 2015 | CN¥553.17 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Jiangxi Fushine Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.25 Billion USD |
| MoneyControl | $1.25 Billion USD |
| MarketWatch | $1.25 Billion USD |
| marketcap.company | $1.25 Billion USD |
| Reuters | $1.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride… Read more